× The federal government has shut down due to the failures of the President and Congress to continue government funding. Millions of Californians receiving benefits from state programs may be impacted. For now, California’s Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) will continue to provide services and enroll eligible families as long as funding is available. No new federal funding to California WIC will be provided until the President and Congress take action. Families should continue to use their WIC benefits and attend their WIC appointments. This information is subject to change, so please monitor the California WIC website for updates.

Please be wary of potential highly partisan political messaging while visiting federal government websites for information related to the federal government shutdown.

Skip Navigation LinksBamlanivimab-Fact-Sheet

Top Menu




State of Cal Logo
EDMUND G. BROWN JR.
Governor

State of California—Health and Human Services Agency
California Department of Public Health


November 5, 2021


TO:
All Californians

SUBJECT:
California Department of Public Health Bamlanivimab Distribution Fact Sheet

​​Note: This Guidance is no longer in effect and is for historical purposes only.


Related Materials:  Ordering of Anti-SARS-CoV-2 Monoclonal Antibodies |  Anti-SARS-CoV-2 Monoclonal Antibody Treatment Information for Providers and Facilities (Q&A) | Bamlanivimab plus Etesevimab Distribution Fact Sheet | Casirivimab and Imdevimab Distribution Fact Sheet | More Healthcare & Testing Guidance | All Guidance | More Languages

Given the sustained increase in variants resistant to bamlanivimab alone, and availability of alternative authorized anti-SARS-CoV-2 monoclonal antibodies, use of bamlanivimab monotherapy is no longer authorized. In March 2021, the California Department of Public Health (CDPH) stopped recommending bamlanivimab monotherapy, and on April 16, 2021, the Food and Drug Administration (FDA) revoked the Emergency Use Authorization (EUA) for bamlanivimab monotherapy.

The currently available anti-SARS-CoV-2 monoclonal antibodies that have received an EUA from the FDA include:

  1. Bamlanivimab plus etesevimab (PDF) (administered together)
  2. Casirivimab plus imdevimab (PDF) (administered together as REGEN-COV) (PDF)
  3. Sotrovimab (PDF)

All three products cover current variants circulating in California.


​Originally published on December 1, 2021